Gangliosides and N-glycoproteins function as Newcastle disease virus receptors.
The interaction of enveloped viruses with cell surface receptors is the first step in the viral cycle and an important determinant of viral host range. Although it is established that the paramyxovirus Newcastle Disease Virus binds to sialic acid-containing glycoconjugates the exact nature of the receptors has not yet been determined. Accordingly, here we attempted to characterize the cellular receptors for Newcastle disease virus. Treatment of cells with tunicamycin, an inhibitor of protein N-glycosylation, blocked fusion and infectivity, while the inhibitor of O-glycosylation benzyl-N-acetyl-alpha-D-galactosamide had no effect. Additionally, the inhibitor of glycolipid biosynthesis 1-phenyl-2-hexadecanoylamino-3-morpholino-1-propanol blocked viral fusion and infectivity. These results suggest that N-linked glycoproteins and glycolipids would be involved in viral entry but not O-linked glycoproteins. The ganglioside content of COS-7 cells was analyzed showing that GD1a was the major ganglioside component; the presence of GM1, GM2 and GM3 was also established. In a thin-layer chromatographic binding assay, we analyzed the binding of the virus to different gangliosides, detecting the interaction with monosialogangliosides such as GM3, GM2 and GM1; disialogangliosides such as GD1a and GD1b, and trisialogangliosides such as GT1b. Unlike with other viruses, our results seem to point to the absence of a specific pattern of gangliosides that interact with Newcastle disease virus. In conclusion, our results suggest that Newcastle disease virus requires different sialic acid-containing compounds, gangliosides and glycoproteins for entry into the target cell. We propose that gangliosides would act as primary receptors while N-linked glycoproteins would function as the second receptor critical for viral entry.
Ferreira
Laura
L
Departamento de Bioquímica y Biología Molecular, Universidad de Salamanca, Edificio Departamental Lab. 108, Plaza Doctores de la Reina s/n, 37007 Salamanca, Spain.
Villar
Enrique
E
Muñoz-Barroso
Isabel
I
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology; D019556:COS Cells; D002522:Chlorocebus aethiops; D002855:Chromatography, Thin Layer; D005732:Gangliosides / Q000378:metabolism*; D006023:Glycoproteins / Q000378:metabolism; D006031:Glycosylation / Q000187:drug effects*; D006367:HeLa Cells; D006801:Humans; D019158:N-Acetylneuraminic Acid / Q000378:metabolism; D009522:Newcastle disease virus / Q000378:metabolism*; D011991:Receptors, Virus / Q000378:metabolism*; D014415:Tunicamycin / Q000494:pharmacology*; D014709:Vero Cells
D000998:Antiviral Agents; D005732:Gangliosides; D006023:Glycoproteins; D011991:Receptors, Virus; D014415:Tunicamycin; D019158:N-Acetylneuraminic Acid